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Abstract: Development of resistance to therapy in ovarian cancer is a major hinderance for therapeutic efficacy; however, new mechanisms of the resistance remain to be elucidated. NADPH
oxidase 4 (NOX4) is responsible for higher NADPH activity to increase reactive oxygen species
(ROS) production. In this study, we showed that higher levels of NOX4 were detected in a large
portion of human ovarian cancer samples. To understand the molecular mechanism of the NOX4
upregulation, we showed that NOX4 expression was induced by HIF-1α and growth factor such
as IGF-1. Furthermore, our results indicated that NOX4 played a pivotal role in chemotherapy
and radiotherapy resistance in ovarian cancer cells. We also demonstrated that NOX4 knockdown
increased sensitivity of targeted therapy and radiotherapy through decreased expression of HER3
(ERBB3) and NF-κB p65. Taken together, we identified a new HIF-1α/NOX4 signal pathway which
induced drug and radiation resistance in ovarian cancer. The finding may provide a new option to
overcome the therapeutic resistance of ovarian cancer in the future.
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1. Introduction
Ovarian cancer is one of the leading causes of cancer-associated death among women.
About 70 percent of patients with ovarian cancer were found to be in advanced stages
(Stages III, IV), chemotherapeutic resistance and tumor recurrence will always occur after
a period of treatment [1]. In the past 10 years, the prevalence rate of ovarian cancer
has significantly increased, but the therapeutic effect has not significantly improved [2].
Therefore, there is an urgent need to find new and tolerable effective methods for the
treatment of ovarian cancer.
Increased reactive oxygen species (ROS) production has been detected in various
cancers and thought to be oncogenic, they were reported to cause genomic instability and
DNA damage [3], contributing to the activation of pro-survival signaling pathway, loss of
tumor suppressor gene-function, and increasing glucose metabolism, resulting in cancer
progression and drug resistance [4]. In our previous study, we found that ROS levels
were significantly increased in ovarian cancer cells compared with normal cells, which
regulated hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor
(VEGF) expression, and induced angiogenesis and tumor growth [5]. NADPH oxidase
4 (NOX4) was responsible for higher NADPH activity to increase ROS production, and
NOX4 mRNA levels were much higher in ovarian cancer cells than those in normal cells [5].
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However, the molecular mechanisms leading to higher levels of NOX4 in ovarian cancer
cells remain to be elucidated.
HER2 (ERBB2) monoclonal antibody trastuzumab has achieved exciting results in
the treatment of breast cancer. Considering that of 9–30% of ovarian cancer patients were
HER2 positive, and there are several similarities of the biology of HER2 between breast
cancer and ovarian cancer, it would be feasible to treat ovarian cancer via HER2 target
therapy [6,7]. However, one Phase II clinical trial confirmed that trastuzumab was not
effective enough in the treatment of ovarian cancer [8], and the reasons were not clear yet.
Our previous study showed that high levels of ROS significantly increased the expression
levels of HER2 and HER3 in ovarian cancer [3]. Therefore, it is interesting to further explore
whether NOX4 is involved in the therapy resistance of ovarian cancer cells.
In this study, we first verified that NOX4 expression levels were elevated in ovarian
cancer tumor tissues. To understand the molecular mechanism of NOX4 upregulation,
we showed the role of HIF-1α in mediating the alternative splicing of NOX4 expression.
Furthermore, we demonstrated that NOX4 played a pivotal role in targeted therapy and
radiotherapy resistance in ovarian cancer cells. Finally, we identified HER3 and NF-κB
p65 were down-stream molecules in NOX4-mediated drug resistance. This work would
provide an experimental basis for further elucidating the molecular mechanism of ovarian
cancer treatment and prognosis judgment in the future.
2. Materials and Methods
2.1. Cell Culture and Transfection
Human ovarian cancer cell lines A2780 and OVCAR3 (kindly provided by Dr. Jing-Jie
Yu at West Virginia University, Morgantown, WV, USA) were cultured in DMEM medium
supplemented with the following components: penicillin (100 units/mL), streptomycin
(100 units/mL) and 10% FBS. Cells were placed at 37 ◦ C incubator with 5% CO2 . The cell
transfection was performed using X-treme GENE HP DNA Transfection Reagent (Roche,
Mannheim, Germany) by following the manufacturer’s instruction. These cells were
cultured in the presence of 1 µg/mL puromycin for 3–4 weeks to select stable cell lines.
2.2. Clinical Ovarian Cancer Specimens
The human ovarian tumor tissues and adjacent normal tissues of ovarian cancer
patients were obtained from the tissue bank of the Affiliated Cancer Hospital of Zhengzhou
University (Zhengzhou, China). The ovarian cancer tissue had been collected and stored
in the tissue bank for several years. The patient information including names, age and
other patient personal information was not known to the investigators. Based on the coded
information, the patients had high-grade serous cell carcinoma (HSCC), but no history of
other tumors and no autoimmune diseases. The patients did not receive surgical treatment,
radiotherapy, chemotherapy or immunization inhibitory therapy before surgery.
2.3. Compounds and Plasmids
GKT137831 (S7171) and afatinib (S1011) were purchased from Selleck (Selleck, Houston, TX, USA), and dissolved in DMSO for stock, and diluted with PBS. All shRNA
plasmids were purchased from Genechem. (Genechem, Shanghai, China). HER2/HER3
cDNA plasmids and HIF-1α knockout plasmids were designed by our laboratory.
2.4. RNA Extraction and Quantitative Real-Time PCR
Total RNAs were extracted and purified using TRIzol reagent (10296010, Thermo
Fisher Scientific, Waltham, MA, USA) by following manufacturer’s instruction. The firststrand cDNAs were synthesized by 1 µg total RNAs (R323-01, Vazyme, Nanjing, China)
and mixed with specific primers, RNase-free water, and ChamQ Universal SYBR qPCR
Master Mix and detected the mRNA expression levels of NOX4 and NOX4C via a real-time
PCR system (Q711-03, Vazyme, Nanjing, China). The relative levels of specific RNAs were
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measured and normalized to expression levels of GAPDH (an internal control). Primers
used were as follows:
NOX4-F Ex1: CCATGGCTGTGTCCTGGAGGAGCTG;
NOX4-R Ex18: CACAGCTGATTGATTCCGCTGAG;
NOX4C-F Ex1: CCATGGCTGTGTCCTGGAGGAGCTG;
NOX4C-R Ex12/8: CAGTTGGACACCTGAAACATG;
GAPDH-F: TGAACGGGAAGCTCACTGG;
GAPDH-R: TCCACCACCCTGTTGCTGTA.
2.5. Western Blotting
Cells were lysed in cell lysis buffer and cell lysate supernatants were obtained by
centrifugation at 13,000× g at 4 ◦ C for 15 min. Aliquots of total proteins (30–40 µg) were
used to perform immunoblotting analysis using the following antibodies: rabbit antiNOX4 (1:1000, ab133303, Abcam, Waltham, MA, USA), rabbit anti-HIF-1α (1:1000, BS3514,
Bioword, Nanjing, China), rabbit anti-HER2 (1:1000, 18299-1-AP, Proteintech, Wuhan,
China), rabbit anti-HER3 (1:1000, 10369-1-AP, Proteintech, Wuhan, China), rabbit anti-NFkB p65 (1:1000, ab16502, Abcam, MA, USA), rabbit anti-β-actin (1:5000, AP0060, Bioword,
Nanjing, China) and rabbit anti-GAPDH (1:5000, AP0063, Bioword, Nanjing, China).
2.6. Cell Viability Assays
Cells were seeded in 96-well plates and cultured overnight. The cell viability was determined 72 h after drug treatment using the CCK-8 Kit (Dojindo Laboratories, Kumamoto,
Japan) according to the manufacturer’s instruction. Briefly, 10 µL of CCK-8 solution were
added to each well, followed by incubation at 37 ◦ C for 1 h. The OD values were measured
at 450 nm using a microplate reader.
2.7. Radiation and Clone Formation
Stable cell lines were irradiated with 6MV X-ray linear accelerator at doses of 0 Gy,
2 Gy, 4 Gy and 6 Gy. The dose rate was 200 Gy/min, the source-target distance was 100
mm. After irradiation, the cells were digested with 0.25% trypsin and counted. Cells were
plated in 6-well plate at corresponding irradiation doses, and plated in 37 ◦ C, 5% CO2
incubator for 10–14 days. The numbers of cells were 300 (0 Gy), 600 (2 Gy), l000 (4 Gy)
and 5000 (6 Gy)/hole as indicated. Then cells were stained with 1% crystal violet solution,
the numbers of cell clones formed in each hole were counted (clones > 50 cells, count as
1 clone). Clone formation rates (PE) and cell survival rates (SF) were calculated, PE =
(number of clones in blank control group/number of cells plated in blank control group) ×
100%, SF = number of clones in irradiated experimental group/(number of cells plated in
blank control group * PE) at a certain dose.
2.8. Luciferase Reporter Assay
Cells were seeded in 24-well plates overnight and transfected with 1 µg promoter
luciferase reporter vector and 0.1 µg renilla luciferase expression vector (pGL4.74). Cells
were harvested 48 h after transfection, and luciferase activities were detected and analyzed
according to the manufacturer’s instructions (E1910, Promega, Madison, WI, USA).
2.9. Database
NOX4 expression levels were detected and analyzed using the cancer genome atlas
(TCGA) dataset. The prognostic values of NOX4 mRNA expression levels were evaluated
using an online database, Kaplan–Meier Plotter. The overall survival (OS) and progression
free survival (PFS) were obtained from the TCGA dataset of NOX4 via probe 236843.
2.10. Statistical Analysis
All calculations were performed using GraphPad Prism 8.0 and presented as mean ± SEM.
If there are only two groups, we analyzed the data by a paired Student’s t-test for paired
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data or Student’s t-test for unpaired data. The difference was considered significant at
p < 0.05. Survival curves of our data were plotted using Kaplan–Meier curve and compared
using the log-rank test.
3. Results
3.1. Higher NOX4 Levels Were Correlated with Ovarian Cancer Development and Poor
Progression-Free Survival

Cells 2021, 10, x FOR PEER REVIEW

In this study, we detected the expression levels of NOX4 in six pairs of human ovarian
cancer tissues and adjacent normal tissues. Our results showed that the expression levels of
NOX4 were significantly higher in the tumor tissues compared with adjacent tissues. The
representative results from the tissues were shown in Figure 1A. Consistently, analysis of
NOX4 mRNA expression levels in the TCGA database showed that NOX4 expression levels
were significantly higher in ovarian cancer tissues than those in normal tissues (Figure 1B).
The Kaplan–Meier curve and log-rank test analyses revealed that NOX4 mRNA levels were
5 of 16(PFS), and
strongly associated with the overall survival (OS) and progression-free survival
higher levels of NOX4 mRNA were significantly associated with the lower OS and PFS in
the ovarian cancer patients in the TCGA database (Figure 1C).

Figure 1. High NOX4 levels were correlated with ovarian cancer development. (A) The expression
levels of NOX4 in tumor tissues of human ovarian cancer patients (N1–N6) and the normal control
samples (T1–T6). (B) The mRNA expression levels of NOX4 in ovarian cancer tissues and normal
tissues obtained from the TCGA database. (C–D) The correlation between NOX4 expression levels
and overall survival (OS) or progression-free survival (PFS) in ovarian cancer patients in the TCGA
database. ** Indicates significant difference at p < 0.01, *** Indicates significant difference at p < 0.001.
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3.2. Expression Levels of NOX4 Were Regulated by HIF-1α via Alternative Splicing in
A2780 Cells
NOX4 has different isoforms produced by alternative splicing for regulating gene
expression [9]. In addition to the full length functional NOX4, the non-functional, dominant
negative isoform NOX4C was produced by cutting off exons from 9 to 11 containing
NAD(P)H/FADH binding regions, resulting in the loss of function [10]. Because ovarian
cancer tissues were known to be hypoxia with higher levels of HIF-1α expression [1,2],
and, as shown in Supplementary Figure S1, the HIF-1α expression levels were high and
were strongly correlated with the overall survival of ovarian cancer patients. Therefore,
we first investigated whether NOX4 was regulated by HIF-1α in A2780 ovarian cancer
cells. Cells were transfected with shHIF-1α and control vector shNC, Western blot analysis
revealed that knockdown of HIF-1α significantly decreased the full length and functional
NOX4 expression (Figure 2A). Furthermore, knockout HIF-1α by CRISPR-cas9 resulted
in significant downregulation of NOX4 in A2780 ovarian cancer cells (Figure 2B). These
results suggested that HIF-1α regulated the expression levels of NOX4.

Figure 2. Expression levels of NOX4 were regulated by HIF-1α via alternative splicing in A2780
cells. (A) Knockdown the expression level of HIF-1α in A2780 cells via the shRNA of HIF-1α (shHIF1α-1 and shHIF-1α-2) and the negative control (shNC), the expression level of NOX4 and HIF-1α
were detected and the respective pictures and the quantitative data (SEM ± SD, n = 3) are shown.
(B) NOX4 mRNA and protein expression level in HIF-1α knockout A2780 cells detected by RT-PCR
and Western blotting. (C) The exons 9–11 skipping NOX4C expression levels in HIF-1α knockout
cells. (D) Cell viability and response to trastuzumab in HIF-1α knockout A2780 cells. ** and ##
indicates significant difference at p < 0.01.

As HIF-1α regulated the alternative splicing of adrenomedullin pre-mRNA [11], we
investigated whether HIF-1α may regulate the splicing of NOX4. Our results indicated that
HIF-1α knockout greatly increased NOX4C mRNA expression levels in A2780 (Figure 2C).

Cells 2021, 10, 1647

6 of 13

We then detected the cell viability and response to trastuzumab in HIF-1α knockout A2780
cells, and our results showed that HIF-1α knockout significantly decreased the cell viability
and increased the therapy sensibility to trastuzumab (Figure 2D). These results suggested
that HIF-1α knockout resulted in lower NOX4 and higher NOX4C expression via alternative
splicing and decreased the cell viability and increased the therapy sensibility in ovarian
cancer cells.
3.3. IGF-1 Treatment Increased the Expression Levels of HIF-1α and NOX4 in A2780 and
OVCAR3 Cells
IGF-1 plays a key role in the development, maintenance and chemotherapeutic response of ovarian cancer [12], and serum concentrations of free IGF-1 were significantly
increased in ovarian cancer patients [13]. Therefore, we tested whether IGF-1 could induce
the expression levels of HIF-1α and NOX4. A2780 and OVCAR3 cells were incubated with
various concentrations of IGF-1 for 4 h; HIF-1α and NOX4 expression levels were analyzed
by Western blot. At the range of physiologically relevant concentrations, IGF-1 markedly
induced HIF-1α and NOX4 expression levels in human ovarian cancer A2780 and OVCAR3
cells (Figure 3A), thus HIF-1α might be one of the mechanisms regulating the expression
level of NOX4. A2780 and OVCAR3 cells were incubated with IGF-I for 0, 2 or 4 h; NOX4
protein levels were induced by IGF-1 treatment in a time-dependent manner (Figure 3B).
The cells were transfected with shHIF-1α and treated with 100 ng/mL IGF-1 for 4 h; NOX4
expression levels were then detected by Western blotting. IGF-1 treatment increased NOX4
expression by 23% in control shNC-transfected cells, while NOX4 expression levels were
decreased by 24% in HIF-1α knockdown cells (Figure 3C). These results suggested that
knockdown of HIF-1α significantly decreased NOX4 expression.
3.4. NOX4 Knockdown Increased the Sensitivity to Trastuzumab Treatment via Downregulating
HER3 in Ovarian Cancer Cells
HER2 and HER3 expression was reported to be involved in drug resistance of ovarian
cancer cells [14–17]. As shown in Supplementary Figure S1, the HER2 and HER3 expression
levels were higher and highly correlated with the overall survival of ovarian cancer patients.
To further evaluate whether forced HER2 or HER3 overexpression was sufficient to reverse
drug resistance, A2780 cells were infected with lentivirus containing either HER2 cDNA
without 30 -UTR (Figure 4A) or HER3 cDNA without 30 -UTR (Figure 4B), stable cell lines
were obtained by puromycin selection. Cells were then treated with trastuzumab treatment
and the effect on cell viability was determined. As shown in Figure 4A,B, trastuzumab
treatment significantly reduced cell viability to 42% of the control in wild type cells. In
HER2 over-expressing cells, trastuzumab treatment reduced cell viability to 36% of the
control (Figure 4A), suggesting a small decrease in sensitivity to trastuzumab treatment. In
contrast, in HER3 over-expressing cells, trastuzumab treatment did not significantly reduce
cell viability compared with the control (Figure 4B), suggesting HER3 is an important
molecule in drug resistance. In order to investigate whether NOX4 is involved in the
targeted therapy resistance of ovarian cancer, we tested whether NOX4 knockdown affected
the sensitivity of ovarian cancer to trastuzumab (HER2 inhibitor) treatment. A2780 stable
cell lines with NOX4 knockdown were obtained through the shNOX4 lentivirus infection
and puromycin selection. Cells were treated with trastuzumab, and cell viability was
examined. As shown in Figure 4C, NOX4 knockdown significantly increased cell sensitivity
to trastuzumab-induced cytotoxicity as compared with control shNC-transfected cells. To
investigate whether NOX4-induced therapeutic resistance via HER3, we found that NOX4
knockdown significantly reduced HER3 expression levels (Figure 4D). Furthermore, NOX4
inhibitor (GKT137831) and another HER2 inhibitor, afatinib, produced a synergistic effect,
as compared with GKT137831 or afatinib alone in A2780 cells (Figure 4E). These results
suggested that the decreased expression of HER3, but not HER2, was the main reason for
increased sensitivity of targeted therapy after NOX4 knockdown.
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Figure 3. IGF-1 treatment increased the expression levels of HIF-1α and NOX4 in A2780 and OVCAR3 cells. (A) Cells were
serum starved for 16 h, and treated with the indicated concentrations of IGF-1 for 4 h. The expression levels of HIF-1α and
NOX4 were detected via Western blotting. (B) The serum-starved cells were treated with 100 ng/mL IGF-1 for 0 to 4 h,
as indicated. The expression levels of NOX4 were analyzed by Western blotting. (C) The HIF-1α knockdown cells were
serum-starved and treated with 100 ng/mL IGF-1 for 4 h, the expression levels of NOX4 were analyzed by Western blotting.
** indicates significant difference at p < 0.01.
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Figure 4. NOX4 knockdown increased the sensitivity to trastuzumab treatment via downregulating
HER3 in ovarian cancer cells. (A,B) Overexpression HER2 and HER3 in A2780 cells; cells were treated
with Trastuzumab and cell viability was detected via CCK8. (C) Knockdown of NOX4 in the cells
via shNOX4; cells were treated with trastuzumab (100 mg/mL) for 4 days, and cell viabilities were
detected by CCK8. * indicates significant difference at p < 0.05 compared with trastuzumab alone or
shNOX4 group, ** indicates significant difference at p < 0.01 compared with trastuzumab alone or
shNOX4 group, # indicates significant difference at p < 0.05, ## iindicates significant difference at
p < 0.01. (D) The expression levels of HER3 in NOX4 knockdown cells were de-tected via Western
blotting. (E) Combination treatment of NOX4 inhibitor (GKT137831) and afatinib; cell viability was
detected after 72 h and CI values were calculated by software CompuSyn.

3.5. Knockdown of NOX4 and HIF-1α Increased Sensitivity to Radiation Therapy in Ovarian
Cancer Cells
In order to explore the role of NOX4 and HIF-1α in the radiation therapy of ovarian
cancer, OVCAR3 cells were transfected with shNOX4 or control shNC vector; at 48 h after
transfection, cells were irradiated with 6MV X-ray linear accelerator at doses of 0 Gy, 2 Gy,
4 Gy and 6 Gy. Then, cells were plated in a 6-well plate and incubated for 10–14 days, the
numbers of cell clones were counted, and survival cells were analyzed. The knockdown
of NOX4 and HIF-1α had no significantly effect to the number of cell clones at 0 Gy
(Figure 5A). As shown in Figure 5B, the number of cell clones significantly decreased in the
NOX4 knockdown group, as compared with the control, indicating that NOX4 knockdown
decreased cell survival and increased radiation sensitivity. Similarly, knockdown of HIF-1α
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by transfection of shHIF-1α also greatly increased radiation sensitivity as compared with
the control (Figure 5C).

Figure 5. Knockdown of NOX4 and HIF-1α increased cell sensitivity to radiation treatment of cancer
cells. (A–C) Knockdown of NOX4 and HIF-1α in OVCAR3 cells was performed using shNOX4 and
shHIF-1α, radiation treatment was performed at 48 h after transfection. The number of cell clones
were counted, and levels of survival cells were analyzed.

3.6. Knockdown of NOX4 Decreased the Transcriptional Activity and Expression Levels of NF-κB
p65, and Increased Sensitivity to Afatinib Treatment in A2780 and OVCAR3 Cells
NF-κB p65 was reported to promote cell proliferation, invasion and migration in
ovarian cancer [18,19]. To investigate whether NOX4 regulates expression of NF-κB p65,
cells were transfected with either lentivirus carrying shNOX4 or control shNC, total proteins
were extracted for Western blotting to analyze NF-κB p65 protein levels. As shown in
Figure 6A, NOX4 knockdown significantly decreased NF-κB p65 expression in A2780 cells.
We also measured NF-κB p65 transcriptional activity using its promoter luciferase reporter
system. Compared with control, knockdown of NOX4 significantly decreased the relative
luciferase activities of NF-κB p65 in both A2780 and OVCAR3 cells (Figure 6B). To explore
whether NF-κB p65 regulated chemotherapeutic resistance, A2780 cells were transfected
with lentivirus carrying NF-κB p65, and stable cell lines were obtained by puromycin
selection. Afatinib was used to treat the cells and the survival cells were analyzed. Results
showed that afatinib treatment decreased cell viability, and knockdown of NF-κB p65
expression further decreased cell viability with afatinib treatment (Figure 6D). These results
suggested that NOX4 regulated the transcriptional activity and expression level of NF-κB
p65, and further regulated sensitivity to afatinib treatment in A2780 and OVCAR3 cells.
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Figure 6. Knockdown of NOX4 in the cells decreased the transcriptional activity and expression level
of NF-κB p65, and increased sensitivity to afatinib treatment in A2780 and OVCAR3 cells. (A) The
expression levels of NF-κB p65 were detected by Western blotting in A2780 cells with knockdown of
NOX4. (B) NF-κB p65 promoter luciferase reporter activities in NOX4 knockdown cells. (C) Cells
were transfected with shNC or shp65 and treated with or without afatinib (3 µM/mL), the levels of
survival cells were determined 4 days later. ** Indicates significant difference compared with shNC
group at p < 0.01, and ## indicates significant difference at p < 0.01 compared with afatinib alone
or shNOX4 group. ** Indicates significant difference at p < 0.01, * indicates significant difference at
p < 0.05.

4. Discussion
Ovarian cancer is the most lethal malignancy among women, mainly due to its
advanced stages when diagnosed, recurrence and resistance to current chemotherapeutic
agents. It has been well documented that HIF-1 and vascular endothelial growth factor
(VEGF) played important roles in the progression of ovarian cancer, angiogenesis and
tumor growth [5]. We reported that ovarian cancer cells had higher expression levels of
NOX4 [5]. In this study, as showed in the overall model of Figure 7, we showed that
NOX4 expression levels were increased in human ovarian cancer tissues, compared with
the adjacent tissues, and higher expression of NOX4 was associated with poor survival
and progression of ovarian cancer. Interestingly, this study showed that HIF-1α directly
regulated NOX4 expression, which is consistent with the previous report that NOX4 was
induced by hypoxia [20,21]. NOX4 was reported to produce different isoforms by cutting
off exons containing NAD(P)H/FADH binding regions. NOX4C is a variant splicing
of exons from 9 to 11, which does not contain any NAD(P)H or FADH binding sites in
proteins by decreasing ROS levels [10]. We found that HIF-1α knockdown induced higher
expression levels of NOX4C.
Drug resistance is a complex phenomenon and the number of genes and signaling
pathways may be involved in this process. Thus, better understanding of molecular
mechanisms is crucial for management of ovarian cancer treatment [22]. HER2 monoclonal
antibody trastuzumab has achieved exciting results in the treatment of breast cancer;
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however, Phase II clinical trials confirmed that trastuzumab is not effective in the treatment
of ovarian cancer [8], which may be due to this novel HIF-1/NOX4 pathway.

Figure 7. Overall model of NOX4 signaling in ovarian cancer.

In this study, we demonstrated that overexpression of HER3, but not HER2, might
be a main reason why trastuzumab was not effective in the treatment of ovarian cancer.
Previously, we revealed that ROS induced HER2 and HER3 expression in ovarian cancer cells [23]; here, we found that NOX4 knockdown decreased the expression level of
HER3, suggesting that NOX4 regulated drug resistance through HER3. We showed that,
while overexpression of HER2 slightly decreased the sensitivity to trastuzumab treatment,
overexpression of HER3 greatly increased the resistance to trastuzumab treatment.
In this study, we also found that combination therapy of NOX4 inhibitor (GKT137831)
and afatinib decreased cell viability and had a synergy effect in ovarian cancer cells, which
might be a strategy for ovarian cancer treatment. Afatinib, also known as BIBW2992, was
shown to have significant benefits in progression-free survival when compared with standard doublet chemotherapy in NSCLC patients with EGFR mutations in two randomized
Phase III trials [24,25]. Afatinib is also a therapeutic option as a HER2-targeted therapy
for NSCLC harboring HER2 amplification or mutations [26]. It has been approved for the
treatment of EGFR-mutant NSCLCs in several countries. The combination of paclitaxel
and afatinib was found to induce significant tumor regressions and tumor necrosis of the
A2780 xenografts [27].
In addition to drug resistance, we found that NOX4 knockdown increased radiation
sensitivity, which is consistent with the study that NOX4 blockage enhances the efficiency
of radiotherapy in glioblastoma multiforme xenografts [28]. Moreover, HIF-1α knockdown also greatly increased radiation sensitivity, indicating that HIF-1α was an effector
of NOX4 for mediating radiation resistance in ovarian cancer cells. Thus, this finding
may be a potential new mechanism of therapeutic resistance with clinical implications in
other cancers.
Taken together, these results indicated that NOX4 may be a novel prognostic marker
and therapeutic target for ovarian cancer. The downstream genes of NOX4, such as HER3
or/and NF-κB, may play important roles in the regulation of therapeutic sensitivity, which
may provide an experimental basis for further investigation into improving ovarian cancer
treatment and prognosis in the future.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cells10071647/s1, Figure S1: The HIF-1α, HER2 and HER3 expression levels.
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